retatrutide clinical trials safety data New Phase 3 just dropped 👀 Eli Lilly's trial reported average weight loss approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats Retatrutide, an Amazing Future for

Cardiovascular benefits: Numerous studies have demonstrated that GLP-1s reduce cardiovascular risk in patients with diabetes or those at high cardiovascular risk, independent of their HbA1c levels

Inflammation and Alzheimers disease

[DOI] [PubMed] [Google Scholar] 44.Raskin P, Mohan A

Sagging and laxity result when the rate of fat loss exceeds the rate of skin retraction, especially when weight loss is rapid, collagen quality is reduced, or the patient already has early laxity

This might include referral to a dietitian for personalised nutritional guidance, a weight management service for structured support, or mental health services if body image concerns or disordered eating patterns are present